Lisa B Nachtigall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128299/publications.pdf

Version: 2024-02-01

		567281	477307
35	880	15	29
papers	citations	h-index	g-index
35	35	35	1047
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Extensive Clinical Experience:Changing Patterns in Diagnosis and Therapy of Acromegaly over Two Decades. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2035-2041.	3.6	112
2	Psychotropic-Induced Hyperprolactinemia: A Clinical Review. Psychosomatics, 2014, 55, 29-36.	2.5	90
3	Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas. International Journal of Radiation Oncology Biology Physics, 2014, 90, 532-539.	0.8	88
4	Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: relationship to spontaneous puberty, testicular volume, and prior treatmenta clinical research center study Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3520-3525.	3 . 6	77
5	Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na $ ilde{A}$ -ve patients with acromegaly. Pituitary, 2010, 13, 115-122.	2.9	61
6	Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3770-3777.	3.6	55
7	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3785-e3797.	3.6	54
8	Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology, 2010, 72, 53-58.	2.4	46
9	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiotherapy and Oncology, 2019, 137, 95-101.	0.6	46
10	Bone microarchitecture and estimated bone strength in men with active acromegaly. European Journal of Endocrinology, 2017, 177, 409-420.	3.7	32
11	Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e532-e543.	3.6	27
12	Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men With Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3181-3191.	3.6	26
13	Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society―survey. Pituitary, 2019, 22, 37-45.	2.9	24
14	Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2271-e2281.	3.6	19
15	The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary, 2014, 17, 366-373.	2.9	18
16	Current treatment options for hyperprolactinemia. Expert Opinion on Pharmacotherapy, 2013, 14, 1611-1625.	1.8	13
17	Kisspeptin Overcomes GnRH Neuronal Suppression Secondary to Hyperprolactinemia in Humans. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3515-e3525.	3.6	13
18	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neuro-Oncology Practice, 2018, 5, 64-68.	1.6	10

#	Article	IF	Citations
19	Mifepristone Increases Thyroid Hormone Requirements in Patients With Central Hypothyroidism: A Multicenter Study. Journal of the Endocrine Society, 2019, 3, 1707-1714.	0.2	10
20	Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary, 2016, 19, 437-447.	2.9	9
21	Hypopituitarism After Cranial Irradiation for Meningiomas: A Single-Institution Experience. Practical Radiation Oncology, 2019, 9, e266-e273.	2.1	9
22	Cabergoline for hyperprolactinemia: getting to the heart of it. Endocrine, 2017, 57, 3-5.	2.3	7
23	Clinical Outcomes and Self-Reported Symptoms in Patients With Acromegaly: An 8-Year Follow-Up of a Lanreotide Study. Endocrine Practice, 2017, 23, 56-65.	2.1	7
24	The biochemical diagnosis of adrenal insufficiency with modern cortisol assays: Reappraisal in the setting of opioid exposure and hospitalization. Clinical Endocrinology, 2022, 96, 21-29.	2.4	5
25	Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature. Pituitary, 2020, 23, 498-506.	2.9	4
26	Quality of life after long-term biochemical control of acromegaly. Pituitary, 2022, 25, 531-539.	2.9	4
27	Acromegaly diagnosed in a young woman presenting with headache and arthritis. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 582-587.	2.8	3
28	Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib. Journal of the Endocrine Society, 2019, 3, 1887-1891.	0.2	3
29	GnRH agonist-associated pituitary apoplexy: a case series and review of the literature. Pituitary, 2021, 24, 681-689.	2.9	3
30	Virtual education programming for patients with acromegaly: a pilot study. European Journal of Endocrinology, 2022, 186, 341-349.	3.7	3
31	Fractionated radiotherapy versus stereotactic radiosurgery for pituitary adenomas. Nature Clinical Practice Neurology, 2008, 4, 134-135.	2.5	1
32	MON-335 Phenocopy of Multiple Endocrine Neoplasia Type 1 (MEN1) Due to a Germline Cell Division Cycle 73 (CDC73) Variant. Journal of the Endocrine Society, $2019, 3, .$	0.2	1
33	Hyperprolactinemia and Pituitary Causes of Amenorrhea. , 2010, , 83-100.		0
34	Macroprolactinoma: Diagnosis and Management in a Patient with Infertility. , 2018, , 1-8.		0
35	Response to letter to the editor from Professor Jean-François Bonneville. Pituitary, 2019, 22, 103-103.	2.9	0